Last updated: July 17, 2026

Application No. 18/041,072

METHODS FOR MAKING DARUNAVIR P2-LIGAND PRECURSORS

Non-Final OA

Filed

Feb 08, 2024

Priority

Aug 11, 2020 — provisional 63/064,279 +1 more

Examiner

MARTIN, KEVIN STEPHEN

Art Unit

1624

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Purdue Research Foundation

OA Round

1 (Non-Final)

Interview Optional

— +24.5% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 75% grant rate with +24.5% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 146 resolved cases, 2023–2026

Examiner Intelligence

MARTIN, KEVIN STEPHEN View full profile →

Grants 75% — above average

Career Allowance Rate

110 granted / 146 resolved

+15.3% vs TC avg

Strong +24% interview lift

Without

With

+24.5%

Interview Lift

resolved cases with interview

Typical timeline

3y 5m

Avg Prosecution

43 currently pending

Career history

179

Total Applications

across all art units

Statute-Specific Performance

§101

0.3%

-39.7% vs TC avg

§103

34.8%

-5.2% vs TC avg

§102

14.5%

-25.5% vs TC avg

§112

36.8%

-3.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 146 resolved cases

Prosecution Timeline

Feb 08, 2024

Application Filed

Mar 04, 2026

Examiner Interview (Telephonic)

Mar 13, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/421,921

Patent 12678431

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS

5y 0m to grant Granted Jul 14, 2026

18/007,641

Patent 12679833

N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS

3y 7m to grant Granted Jul 14, 2026

18/023,696

Patent 12673106

MODULATORS OF NUCLEAR RECEPTOR SUBFAMILY 4 GROUP A MEMBER 1 (NR4A1) AND USES THEREOF

3y 4m to grant Granted Jul 07, 2026

17/413,991

Patent 12667552

DIETARY BUTYRATE

5y 0m to grant Granted Jun 30, 2026

17/883,743

Patent 12662465

EGFR INHIBITORS

3y 10m to grant Granted Jun 23, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

75%

Grant Probability

99%

With Interview (+24.5%)

3y 5m (~11m remaining)

Median Time to Grant

Low

PTA Risk

Based on 146 resolved cases by this examiner. Grant probability derived from career allowance rate.